If you or a loved one has been diagnosed with colorectal cancer, you may have heard your care team mention “biomarker testing” or “molecular profiling.” These tests look at the specific genetic features of your tumor and the results can directly shape which treatments are most likely to work for you. Three of the most important colorectal cancer biomarkers are RAS, BRAF, and MSI. Here’s a plain-language guide to what they mean.
Why biomarker testing matters
No two colorectal cancers are exactly alike. Two tumors that look identical under a microscope can behave very differently depending on the genetic mutations driving them. Biomarker testing, usually performed on a tissue sample from a biopsy or surgery, and increasingly through blood-based liquid biopsy, identifies these differences.
Current guidelines from major oncology organizations recommend that everyone with metastatic colorectal cancer be tested for RAS (KRAS and NRAS), BRAF V600E, and mismatch repair/MSI status, ideally early in the treatment journey. These results help your oncologist choose targeted therapies, predict prognosis, and avoid treatments unlikely to help.
RAS (KRAS and NRAS): a guide to targeted therapy
The RAS gene family, which includes KRAS and NRAS, is the most commonly tested colorectal cancer biomarker. It’s reported that mutations in these genes occur in up to 45% of colorectal cancers.
The key takeaway: if your tumor has a RAS mutation, a class of drugs called anti-EGFR therapies (such as cetuximab and panitumumab) is unlikely to help, because the mutation drives cancer growth in a way these drugs cannot block. If your tumor is RAS wild-type (meaning no mutation is found), anti-EGFR therapy may be a valuable option, often alongside chemotherapy.
There’s also encouraging news for one specific mutation. Tumors with a KRAS G12C alteration can now be treated with newer targeted drugs (sotorasib or adagrasib) combined with an anti-EGFR agent. This is an example of how a once “undruggable” target has become actionable.
BRAF V600E: an important prognostic and treatment marker
The BRAF V600E mutation is found in roughly 5-10% of colorectal cancers and tends to occur more often in tumors on the right side of the colon. Historically, this mutation has been associated with a more aggressive disease course and shorter survival, which is why identifying it early is so important.
The good news is that treatment has advanced significantly. For BRAF V600E–mutated metastatic disease, guidelines now recommend the targeted drug encorafenib combined with cetuximab (an anti-EGFR drug), sometimes added to chemotherapy such as FOLFOX. Clinical trials have shown that this combination meaningfully improves response rates compared with older standard treatments, giving patients with this mutation more effective options than were available just a few years ago.
MSI and MMR: the door to immunotherapy
MSI stands for microsatellite instability, and it is closely related to MMR (mismatch repair) status. Your report may describe your tumor as MSI-High (MSI-H) or mismatch repair deficient (dMMR). These terms point to the same biological process: the cell’s DNA “spell-check” system isn’t working properly, leading to many mutations.
This matters enormously for treatment. Tumors that are MSI-H/dMMR often respond very well to immunotherapy (immune checkpoint inhibitors), which helps the immune system recognize and attack cancer cells. For many patients with MSI-H colorectal cancer, immunotherapy is now a preferred treatment option.
MSI results can carry one more piece of important information. Because MSI-H status is sometimes linked to Lynch syndrome, an inherited condition that raises cancer risk, your care team may recommend genetic counseling. This can have implications not just for you, but for family members as well.
What your results mean for you
Biomarker results are most powerful when interpreted in the full context of your diagnosis—your tumor’s stage, location, and your overall health. A few helpful questions to ask your oncologist:
- Which biomarkers were tested, and what were my results?
- How do these results affect my treatment options?
- Am I a candidate for targeted therapy or immunotherapy?
- Should I consider genetic counseling for Lynch syndrome?
Understanding your RAS, BRAF, and MSI results empowers you to be an active partner in your care. Precision medicine has transformed colorectal cancer treatment, and your biomarker profile is the map that guides the way forward.
This article is for educational purposes only and is not a substitute for professional medical advice. Always discuss your specific biomarker results and treatment options with your oncology care team.
